- 🇸🇦 Saudi Stock Market
- 🇺🇸 USA Stock Market
Amneal Pharmaceuticals, Inc. and its subsidiaries develop, manufacture, market, and distribute generics, injectables, biosimilars, and specialty branded drugs globally. The company has three segments: Generics, Specialty, and AvKARE. The Generics segment provides various forms of medications, including oral solids, injectables, and topical products. The Specialty segment focuses on drugs for central nervous system and endocrine disorders, offering products like Rytary for Parkinson’s disease and Unithroid for hypothyroidism. The AvKARE segment supplies pharmaceuticals and medical products mainly to government agencies and the Department of Defense, also distributing under the AvKARE and AvPAK brands. Products are sold through wholesalers, hospitals, and pharmacies. Founded in 2002 and based in Bridgewater, New Jersey, the company was previously known as Atlas Holdings, Inc. before rebranding in 2018.
AMRX — NASDAQ —
Current RSI of this stock is 59.32, which indicates the strength of buyers.
MACD line is about to cross the signal line from the below, generates bullish signal.
The short length exponential moving average (10 EMA) has crossed the long length exponential moving average (20 EMA) from the below, generates bullish signal. Last day’s candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.
Based on our US swing trading stocks, Amneal Pharmaceuticals stock price target will be USD 9.1 - USD 9.25 in the next 12-14 trading sessions.
